Wall Street analysts are cutting price targets across defense and pharmaceuticals, even as NVDA keeps attracting bullish upgrades.
NVDA's consensus target rose twice in quick succession, now sitting at $273.73. The chip giant has 55 buy ratings and just 3 holds. Short sellers remain largely absent, with SI at just 1.2% of free float.
Defense names felt the knife. NOC saw its average target trimmed to $706.82 from $711.59. LMT followed, slipping to $635.25 from $637.60. Both stocks carry more holds than buys, reflecting caution over budget headwinds.
REGN took the sharpest pharma cut. The consensus target dropped to $867.88 from $875.31. Regeneron holds 21 buy ratings, but analysts appear wary of near-term pressure on Dupixent growth.
The restaurant sector also saw broad activity. Analysts removed recommendations from MCD, , , and simultaneously. and both saw targets trimmed, signaling softer consumer spending expectations across the board.
The pattern is clear: mega-cap tech keeps drawing upgrades while defensive and consumer-facing names face growing analyst caution.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
